Vytorin vs. Praluent

See how Vytorin and Praluent compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Vytorin is a daily pill combining a statin and a cholesterol absorption inhibitor, while Praluent is a self-injected PCSK9 inhibitor given every two to four weeks.

  • Praluent carries an FDA-approved indication for reducing heart attack, stroke, and hospitalization risk in people with existing cardiovascular disease, a claim Vytorin's label does not include.

  • Vytorin's main risks relate to statin-linked muscle and liver effects, while Praluent's most common side effects are cold-like symptoms and injection site reactions.

Vytorin vs. Praluent Drug Summary

Vytorin

Vytorin combines the statin simvastatin with the cholesterol absorption inhibitor ezetimibe in one daily tablet. It is FDA-approved to lower LDL cholesterol, total cholesterol, and triglycerides in primary hyperlipidemia, as well as to treat homozygous familial hypercholesterolemia and sitosterolemia.

Praluent

Praluent is a PCSK9 inhibitor given as a self-injection every two weeks or, at a higher dose, once a month. It is FDA-approved to lower LDL cholesterol as an add-on to statin therapy, treat heterozygous familial hypercholesterolemia, and reduce cardiovascular event risk in adults with established heart disease.

Vytorin vs. Praluent Side Effects

Vytorin

Most common
Headache (up to 5.8%)
Increased ALT (up to 3.7%)
Myalgia (up to 3.6%)
Upper respiratory tract infection (up to 3.6%)

Praluent

Most common
Nasopharyngitis (up to 11.3%)
Injection site reactions (up to 7.2%)
Influenza (up to 5.7%)
Urinary tract infection (up to 4.8%)

Vytorin vs. Praluent Dosage

Vytorin

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg/10 mg At the start
Maximum dose 10 mg/80 mg If needed
Dose changes 3 increases As tolerated

Praluent

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 75 mg At the start
Maximum dose 300 mg If needed
Dose changes 2 increases As tolerated

Vytorin vs. Praluent Indications

Vytorin

Vytorin is approved for people with primary hyperlipidemia who need to lower LDL, total cholesterol, and triglycerides while raising HDL. It also treats two rare inherited conditions, homozygous familial hypercholesterolemia and homozygous sitosterolemia. It is not approved for use in active liver disease.

  • Lowers LDL, total cholesterol, and triglycerides

  • Raises HDL cholesterol

  • Treats homozygous familial hypercholesterolemia

  • Treats homozygous sitosterolemia

Praluent

Praluent is approved as an add-on to maximally tolerated statin therapy for adults with primary hyperlipidemia who need further LDL lowering. It also treats heterozygous familial hypercholesterolemia in patients 8 and older and reduces the risk of heart attack, stroke, and hospitalization for unstable angina in adults with established cardiovascular disease.

  • Add-on LDL lowering with statin therapy

  • Treats heterozygous familial hypercholesterolemia (ages 8+)

  • Reduces risk of heart attack and stroke

  • Reduces hospitalization for unstable angina

Vytorin vs. Praluent Pros and Cons

Vytorin

Vytorin pairs a statin with a cholesterol absorption inhibitor in one daily pill, giving two mechanisms of LDL reduction without an injection. It carries the class risks of statins, including muscle aches and liver enzyme changes, and its highest dose is reserved for patients who already tolerate it well. As an oral combination pill, it is typically a more familiar first-line option for insurance coverage than an injectable biologic.

Pros

  • Oral tablet with no injections needed

  • Combines two LDL-lowering mechanisms in one pill

  • Multiple dose strengths to match different LDL goals

  • Approved for homozygous familial hypercholesterolemia and sitosterolemia

Cons

  • Carries statin risk of myopathy and rhabdomyolysis

  • Requires liver enzyme monitoring due to hepatotoxicity risk

  • Interacts with strong CYP3A4 inhibitors, limiting other medications

  • Not FDA-approved specifically for cardiovascular event reduction

Praluent

Praluent is a self-injected antibody that blocks PCSK9, lowering LDL cholesterol and carrying proven cardiovascular outcome data. It avoids statin-related liver and muscle risks but requires learning self-injection and cold storage of the pen. As a biologic with no generic version, it usually needs prior authorization from insurance before it is covered.

Pros

  • FDA-approved to reduce risk of heart attack, stroke, and unstable angina hospitalization

  • Avoids statin-related liver and muscle monitoring requirements

  • Flexible dosing: every 2 weeks or once monthly

  • Approved for heterozygous familial hypercholesterolemia starting at age 8

Cons

  • Requires self-injection rather than a pill

  • Pen must be refrigerated until ready to use

  • Not approved for homozygous familial hypercholesterolemia

  • No generic or biosimilar version currently available

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.